Skip to main content
. Author manuscript; available in PMC: 2016 Jun 15.
Published in final edited form as: Bioorg Med Chem. 2015 Mar 31;23(12):2798–2809. doi: 10.1016/j.bmc.2015.03.066

Scheme 1.

Scheme 1

Synthesis of salicylic acid-based UBLCP1 inhibitors. Reaction conditions: (a) Methyl 2-bromohexanoate, K2CO3, DMSO, rt, 96%; (b) R3CCH, pd(pph3)2Cl2, Cul, DMF, rt, overnight, 75–89%; (c) LiOH, MeOH/H2O, reflux 90–95%; (d) R1R2NH, HBTU, HOBt, DIPEA, DMF, 70–80%.